LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature ...
PharmaCyte is a biotechnology company that is currently evaluating its signature live-cell encapsulation technology, Cell-in-a-Box®, for potential development of cellular therapies for cancer, ...
LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a ...
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...
LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, ...
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation ...
PharmaCyte Biotech, a clinical-stage biotechnology company, announced that it has successfully completed the second Container Closure Integrity (CCI) test that is required by the US Food and Drug ...
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global ...
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunities PharmaCyte Biotech, Inc. PMCB ("PharmaCyte" or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results